Dr. Kai-Thomas Schneider

Dr. Kai-Thomas Schneider

Department of Biotechnology

Group Leader, Antibody Switch Technologies

Room:P102a
Phone:+49.531.391.5759
email: kai-thomas.schneider(at)tu-braunschweig.de

Research interests

  • Design, development, and characterization of switchable antibody formats for therapeutic applications and mild affinity purification
  • Protein engineering, phage display, in vitro evolution
  • Optimization of binding assays and screening workflows
  • Bispecific antibodies, CAR T cells 

Curriculum vitae

08/2025-ongoing        Group Leader & Cand. habil. at TU Braunschweig, Department of Biotechnology

04/2019-03/2025        PhD student at  TU Braunschweig, Department of Biotechnology, “Allosteric Regulation of Antibody Affinity”

10/2016 – 03/2019      Master of Science Biotechnology at TU Braunschweig, Master’s Thesis „Entwicklung eines Lyophilisierungsprotokolls für scFv-Fc-Antikörper“

10/2013 – 12/2016      Bachelor of Science Biotechnology at TU Braunschweig, Bachelor’s Thesis „Optimierung der heterologen Produktion von Violacein und Deoxyviolacein in Escherichia coli“

Awards

  • Innovationspreis Niedersachsen (as member of the Corona Antibody Team, 2020)                             

Publications and Patents

Ballmann, R., Schneider, K.‑T., Roth, K. D. R., & Dübel, S. (2023). Antibody Batch Cloning. Methods in Molecular Biology (Clifton, N.J.), 2702, 411–417. doi.org/10.1007/978-1-0716-3381-6_21

Steinke, S., Roth, K. D. R., Ruschig, M., Langreder, N., Polten, S., Schneider, K.‑T., Ballmann, R., Russo, G., Zilkens, K. J. K., Schubert, M., Bertoglio, F., & Hust, M. (2023). Antibody Selection via Phage Display in Microtiter Plates. Methods in Molecular Biology (Clifton, N.J.), 2702, 247–260. doi.org/10.1007/978-1-0716-3381-6_12

Russo, G., Unkauf, T., Meier, D., Wenzel, E. V., Langreder, N., Schneider, K.‑T., Wiesner, R., Bischoff, R., Stadler, V., & Dübel, S. (2022). In vitro evolution of myc-tag antibodies: In-depth specificity and affinity analysis of Myc1-9E10 and Hyper-Myc. Biological Chemistry, 403(5-6), 479–494. doi.org/10.1515/hsz-2021-0405

Jaron, M., Lehky, M., Zarà, M., Zaydowicz, C. N., Lak, A., Ballmann, R., Heine, P. A., Wenzel, E. V., Schneider, K.‑T., Bertoglio, F., Kempter, S., Köster, R. W., Barbieri, S. S., van den Heuvel, J., Hust, M., Dübel, S., & Schubert, M. (2022). Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment. Viruses, 14(10), 2087. doi.org/10.3390/v14102087

Schneider, K.-T., Kirmann, T., Wenzel, E. V., Grosch, J.‑H., Polten, S., Meier, D., Becker, M., Matejtschuk, P., Hust, M., Russo, G., & Dübel, S. (2021). Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization. Frontiers in Cellular and Infection Microbiology, 11, 717689. doi.org/10.3389/fcimb.2021.717689

Bertoglio, F., Meier, D., Langreder, N., Steinke, S., Rand, U., Simonelli, L., Heine, P. A., Ballmann, R., Schneider, K.‑T., Roth, K. D. R., Ruschig, M., Riese, P., Eschke, K., Kim, Y., Schäckermann, D., Pedotti, M., Kuhn, P., Zock-Emmenthal, S., Wöhrle, J., . . . Hust, M. (2021). Sars-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 12(1), 1577. doi.org/10.1038/s41467-021-21609-2

Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., Ballmann, R., Schneider, K.‑T., Roth, K. D. R., Kuhn, P., Riese, P., Schäckermann, D., Korn, J., Koch, A., Chaudhry, M. Z., . . . Hust, M. (2021). A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports, 36(4), 109433. doi.org/10.1016/j.celrep.2021.109433

Patent application: Frenzel, A., Kuhn, P., Kügler, J., Hust, M., Dübel, S., Meier, D., Bertoglio, F., Schubert, M., Steinke, S., Becker, M., Ruschig, M., Schneider, K.‑T., Ballmann, R., Zock-Emmenthal, S., Roth, K. D. R., & Langreder, N. (2021). Therapeutic Antibodies with Neutralizing Activity Against SARS-CoV-2 Glycoprotein S (EP3919126A1). (Priority Date 2020)

Roth, K. D. R., Wenzel, E. V., Ruschig, M., Steinke, S., Langreder, N., Heine, P. A., Schneider, K.‑T., Ballmann, R., Fühner, V., Kuhn, P., Schirrmann, T., Frenzel, A., Dübel, S., Schubert, M., Moreira, G. M. S. G., Bertoglio, F., Russo, G., & Hust, M. (2021). Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Frontiers in Cellular and Infection Microbiology, 11, 697876. doi.org/10.3389/fcimb.2021.697876
 

ORCID (Original Citation ID)

LinkedIn